Tevogen Bio Holdings Bolsa (NASDAQ: TVGN)

Últimas noticias sobre Tevogen Bio Holdings (NASDAQ:TVGN) Bolsa

TEVOGEN BIO HOLDINGS INC

Tevogen Bio Holdings

Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACON

ALUR

ASST

AVBP

CNOB

DWTX

HSTM

IPHA

LGTY

MDXG

The Marygold Companies, Inc. Common Stock

MGLD

MULN

ONCO

PXLW

RMBI

TVGN

VINC

Explora los movimientos más destacados del pre-mercado, incluyendo el aumento del 23% en Logility y más sorpresas.

Acciones de Logility Supply Chain (LGTY) suben un 23%; 20 acciones que se mueven en el premercado de EE.UU.

Tevogen Bio Holdings Inc

<a href="https://www.wsj.com/business/kraft-heinz-is-ditching-artificial-dyes-bcd4626d">https://www.wsj.com/business/kraft-heinz-is-ditching-artificial-dyes-bcd4626d</a>&nbsp;

Wall Street Journal Reported Kraft Heinz Will Remove Artificial Dyes From U.S. Products Before End of 2027, Including Kool-Aid, Jell-O, Crystal Light

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Disc Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRON#NASDAQ">IRON</a>) with a Buy and maintains $118 price target.

Price Target

Reiteration

Analyst Ratings

IRON

HC Wainwright & Co. Reiterates Buy on Disc Medicine, Maintains $118 Price Target

VTYX

Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates Perpetua Resources (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPTA#NASDAQ">PPTA</a>) with a Buy and maintains $27.5 price target.

PPTA

HC Wainwright & Co. Reiterates Buy on Perpetua Resources, Maintains $27.5 Price Target

W&T Offshore Reaches Settlement With Surety Providers, Locks In Premium Rates And Avoids Collateral Demands Through 2026

<ul>
<li>Verve's leading programs aim to deliver lifelong cardiovascular risk reduction with a single dose by targeting genes strongly linked to cardiovascular disease</li>
<li>Lilly's established capabilities in cardiometabolic disease and genetic medicines are highly complementary to Verve's vision and expertise</li>
</ul>

Biotech

Health Care

General

VERV

Eli Lilly Agrees To Acquire Verve Therapeutics For $10.50/Share In Cash (An Aggregate Of Approximately $1B) Plus One Contingent Value Right Of Up To An Additional $3.00 Per Share, For A Total Potential Consideration Of Up To $13.50 Per Share (An Aggregate Of Up To Approximately $1.3B)

Needham analyst Ami Fadia reiterates Cogent Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COGT#NASDAQ">COGT</a>) from Hold to Hold.

COGT

Needham Reiterates Hold on Cogent Biosciencesto Hold

International Game Technology&nbsp;PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGT#NYSE">IGT</a>) ("IGT") announced today that its global lottery organization will begin doing business as Brightstar Lottery ("Brightstar" or the "Company"), effective immediately.
Upon completion of the sale of IGT's Gaming and Digital business ("IGT Gaming"), which is expected to occur as early as July 1, 2025, to Voyager Parent, LLC, a holding company owned by funds managed by affiliates of Apollo Global Management, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) (the "Buyer"), Brightstar will be a premier pure play lottery business designed to elevate lotteries and inspire players.
 &nbsp;

International Game Technology's Global Lottery Organization To Begin Doing Business As Brightstar Lottery, Effective Immediately

RPM International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPM#NYSE">RPM</a>) today announced the acquisition of Ready Seal Inc. (Ready Seal), a Texas-based manufacturer of premium exterior wood stains, for its Rust-Oleum business in the Consumer Group. Ready Seal's high performance and user-friendly "Goof-Proof&#x2122;" stain-and-sealer-in-one can be applied in hot or cold conditions, does not show lap marks, and does not require back brushing. Ready Seal generated calendar year 2024 sales of approximately $45 million. Terms of the transaction were not disclosed.
This strategic acquisition strengthens Rust-Oleum's portfolio of exterior wood care products, a segment that continues to gain traction among professional contractors and DIY enthusiasts. Additionally, Rust-Oleum is positioned to leverage its sales force and distribution channels to accelerate sales of Ready Seal's products.

RPM Buys Ready Seal For Terms Undisclosed to Boost Rust-Oleum's Wood Care Line for Pros and DIYers

TD Securities analyst Andrew Charles reiterates Wingstop (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WING#NASDAQ">WING</a>) with a Buy and maintains $440 price target.

WING

TD Securities Reiterates Buy on Wingstop, Maintains $440 Price Target

Oracle Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) announced on Tuesday the establishment of the Oracle Defense Ecosystem, a new global initiative aimed at enhancing the <a href="https://www.benzinga.com/pressreleases/25/06/n45966059/oracle-launches-first-of-its-kind-defense-ecosystem-to-redefine-national-security-innovation">delivery of technology innovation</a> to defense and government sectors.
The ecosystem is designed to strengthen U.S. and allied national security. It seeks to accelerate the adoption of emerging defense technologies by providing defense innovators with opportunities to utilize cloud and artificial intelligence (AI) capabilities.
Oracle Defense Ecosystem provides defense technology innovators with access to Oracle&#8217;s cloud and AI technologies, sales support, compliance guidance (CMMC, SCCA), and business tools (Palantir, NetSuite). 
Also Read: <a href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/06/45912952/oracles-ai-ambitions-take-flight-after-record-cloud-growth-what-do-analysts-really-think" target="_blank" rel="noreferrer noopener">Oracle&#8217;s AI Ambitions Take Flight After Record Cloud Growth: What Do Analysts Really Think?</a>
It seeks to address the challenges faced by national security teams in accessing cutting-edge cloud and AI technologies, particularly from emerging vendors, due to complex procurement processes and strict qualification standards.
The ecosystem will utilize Oracle Cloud Infrastructure (OCI), which is trusted by the defense and government sector and meets stringent compliance requirements.
Initial members of the Oracle Defense Ecosystem include Arqit,&nbsp;Blackshark.ai, Entanglement, Fenix Group, now part of Nokia Federal Solutions, Koniku, Kraken, Mattermost, Metron, SensusQ, and Whitespace.
The company announced Oracle Compute Cloud@Customer Isolated, a secure, sovereign compute cloud service <a href="https://www.benzinga.com/pressreleases/25/06/n45966054/oracle-advances-national-security-with-new-sovereign-air-gapped-cloud-offering" target="_blank" rel="noreferrer noopener">that can be</a> disconnected from the internet. 
This service provides governments and regulated industries with the required level of security and control for confidential data. 
For governments, ministries of defense, intelligence agencies, and telecommunications and healthcare organizations, Oracle Compute Cloud@Customer Isolated is designed to help minimize risks of attacks, adhere to stringent regulations, and support national security.
Oracle and Nextcloud, a European company, <a href="https://www.benzinga.com/pressreleases/25/06/n45966053/oracle-and-nextcloud-deliver-collaboration-capabilities-to-governments-and-enterprises" target="_blank" rel="noreferrer noopener">announced a partnership</a> that will bring&nbsp;Nextcloud Hub, an open-source content collaboration platform that enables teams to collaborate across mobile, desktop, and web interfaces, to&nbsp;Oracle Cloud Infrastructure&nbsp;(OCI). 
Government and enterprise customers can deploy Nextcloud Hub across OCI&#8217;s&nbsp;sovereign cloud solutions, including public, government, dedicated, and air-gapped regions.
Oracle partnered with&nbsp;Metron to provide <a href="https://www.benzinga.com/pressreleases/25/06/n45966027/oracle-and-metron-strategic-alliance-accelerates-defense-decision-superiority" target="_blank" rel="noreferrer noopener">scalable decision support</a> solutions for multi-domain operations. Oracle and Metron solutions enable defense organizations to outpace their adversaries in the OODA (observe, orient, decide, and act) loop by providing them with the tools to make swift, informed decisions based on data insights, the company said in a press release. 
In addition,&nbsp;Oracle Cloud Infrastructure (OCI),&nbsp;available across all U.S. security fabrics, offers a scalable, high-performance, and cost-effective way for Metron&#8217;s decision support technology to help defense organizations bolster their data security and resilience across battlefield networks.
In another significant defense news development, OpenAI&nbsp;bagged a $200 million <a href="https://www.benzinga.com/markets/tech/25/06/45965573/openai-wins-200-million-us-defense-contract-for-ai-warfare-capabilities-as-the-company-looks-to-raise-40-billion" target="_blank" rel="noreferrer noopener">defense contract to</a> develop artificial intelligence capabilities for national security applications, according to Department of Defense contracts on Monday.
ORCL Price Action:&nbsp;Oracle stock is trading lower by 0.76% to $209.50 premarket at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45928757/amd-serious-ai-contender-with-sights-on-over-500-billion-tam-billions-in-revenue-analyst" target="_blank" rel="noreferrer noopener">AMD &#8216;Serious AI Contender&#8217; With Sights On Over $500 Billion TAM, Billions In Revenue: Analyst</a></li>
</ul>
Image by DC Studio via Shutterstock

Tech

ORCL

Oracle Launches New Defense Program To Help US Military Tap Into AI And Cloud Tech

Needham analyst Laura Martin maintains Taboola.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBLA#NASDAQ">TBLA</a>) with a Buy and raises the price target from $3.34 to $4.5.

TBLA

Needham Maintains Buy on Taboola.com, Raises Price Target to $4.5

Fired vaccine experts warn that Health Secretary Robert F. Kennedy Jr.&#8217;s overhaul of the Centers for Disease Control and Prevention&#8217;s key vaccine advisory panel threatens public health and <a href="https://www.benzinga.com/news/25/06/45937422/rfk-jr-appointee-to-cdc-advisory-committee-was-a-paid-expert-in-mercks-gardasil-lawsuit">undermines decades of immunization progress</a>.
What Happened: Seventeen ousted members of the CDC&#8217;s Advisory Committee on Immunization Practices published a warning in the JAMA medical journal on Monday, condemning Kennedy&#8217;s abrupt dismissal of the entire panel on June 9.
Kennedy replaced them with eight new members, including vaccine critics Robert Malone and Retsef Levi.
&#8220;The abrupt dismissal of the entire membership of the ACIP, along with its executive secretary, on June 9, the appointment of 8 new ACIP members just 2 days later, and the recent reduction of CDC staff dedicated to immunizations have left the U.S. vaccine program critically weakened,&#8221; the former members wrote.
See Also: <a href="https://www.benzinga.com/crypto/25/06/45967028/max-keiser-once-predicted-bitcoin-could-hit-a-300-trillion-market-cap-heres-how-much-1-btc-would-be-worth-if-that-happens">Max Keiser Once Predicted Bitcoin Could Hit A $300 Trillion Market Cap — Here&#8217;s How Much 1 BTC Would Be Worth If That Happens</a>
Why It Matters: Kennedy justified the overhaul to &#8220;re-establish public confidence in vaccine science,&#8221; claiming former President Joe Biden-appointed members had conflicts of interest without providing specific evidence. 
The committee advises the CDC on immunization schedules after U.S. Food and Drug Administration approval, directly influencing insurance coverage and vaccine policy, reported Reuters.
The panel shake-up compounds broader pharmaceutical industry disruption. The Trump administration <a href="https://www.benzinga.com/news/health-care/25/06/45898417/rfk-jr-appoints-vaccine-critics-to-cdc-vaccine-panel-after-firing-entire-advisory-committee-report">terminated a $600 million</a> Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) contract for mRNA bird flu vaccine development and removed COVID-19 vaccines from recommended schedules for pregnant women and children.
Kennedy&#8217;s broader healthcare restructuring eliminated 10,000 U.S. Department of Health and Human Services positions to save $1.8 billion annually. 
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/06/45967060/senate-republicans-unveil-trump-tax-and-health-plan-with-5-trillion-debt-ceiling-hike-tighter-medicaid-rules-in-the-big-beautiful-bill">Senate Republicans Unveil Trump Tax And Health Plan With $5 Trillion Debt Ceiling Hike, Tighter Medicaid Rules In The &#8216;Big, Beautiful Bill&#8217;</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image Via Shutterstock

MRNA

Robert F. Kennedy Jr.'s CDC Overhaul 'Critically Weakened' US Vaccine Program, Say Ousted Experts

<ul>
<li>LYL314 demonstrated robust clinical responses, with an 88% overall response rate and a 72% complete response rate in patients treated in the third- or later-line setting (N = 25)</li>
<li>71% of patients with complete response remained in complete response at ≥ 6 months</li>
<li>Manageable safety profile appropriate for outpatient administration with no Grade ≥ 3 cytokine release syndrome and low rates of Grade ≥ 3 ICANS with rapid resolution</li>
<li>Pivotal single-arm PiNACLE trial is underway in CAR T-naïve patients with large B-cell lymphoma treated in the third- or later-line setting</li>
</ul>

LYEL

Lyell Immunopharma Announced New Clinical Data From Phase 1/2 Trial Of LYL314, In Patients Treated In The 3L+ Setting (N = 25), LYL314 Showed An 88% Overall Response Rate And A 72% Complete Response Rate

SRFM

Surf Air Mobility Achieves Record Reliability And Operational Gains In Optimization Phase Of Transformation Plan

Needham analyst Laura Martin reiterates Roku (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) with a Buy and maintains $88.5 price target.

ROKU

Needham Reiterates Buy on Roku, Maintains $88.5 Price Target

BJ's Wholesale Club Plans New Location in Springfield, Massachusetts; Springfield Club Marks First New Massachusetts Location Since 2012

RACE

Reuters Reported Ferrari Delays Second EV Model Launch to 2028 From 2026 Citing Low Demand for High-Performance Luxury EVs; First EV, a Large Car (Not SUV), to Be Presented Later in 2025

The Kroger Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) will release its first-quarter financial results before the <a href="https://www.benzinga.com/quote/KR/earnings">opening bell on Friday, June 20</a>.
Analysts expect the Cincinnati, Ohio-based company to report quarterly earnings at $1.46 per share, up from $1.43 per share in the year-ago period. Kroger projects quarterly revenue of $45.31 billion, compared to $45.27 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On March 6, the company reported fourth-quarter adjusted earnings per share of $1.14, beating the street view of $1.11. Quarterly sales of $34.308 billion missed the analyst consensus estimate of $34.509 billion.
Kroger shares gained 0.7% to close at $66.01 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/GBX/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Telsey Advisory Group analyst Joseph Feldman maintained an Outperform rating with a price target of $73 on June 13, 2025. This analyst has an accuracy rate of 66%.</li>
<li>Morgan Stanley analyst Simeon Gutman maintained an Equal-Weight rating and raised the price target from $65 to $71 on May 19, 2025. This analyst has an accuracy rate of 65%.</li>
<li>JP Morgan analyst Ken Goldman maintained an Overweight rating and boosted the price target from $72 to $82 on May 1, 2025. This analyst has an accuracy rate of 77%.</li>
<li>Guggenheim analyst John Heinbockel maintained a Buy rating and raised the price target from $71 to $73 on April 3, 2025. This analyst has an accuracy rate of 63%.</li>
<li>Citigroup analyst Paul Lejuez maintained a Neutral rating and boosted the price target from $61 to $65 on March 7, 2025. This analyst has an accuracy rate of 64%</li>
</ul>
Considering buying KR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/kr/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="589" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17024424/image-251-1024x589.png" alt="" class="wp-image-951681" style="width:612px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17024424/image-251-1024x589.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17024424/image-251-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17024424/image-251-768x442.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17024424/image-251.png 1098w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45948533/top-2-financial-stocks-that-may-plunge-in-q2">Top 2 Financial Stocks That May Plunge in Q2</a> </li>
</ul>
Photo via Shutterstock

Earnings

Top Wall Street Forecasters Revamp Kroger Expectations Ahead Of Q1 Earnings

SPNS

Sapiens Unveils Latest CoreSuite Release With Gen AI, ML Tools To Boost Life Insurer Efficiency And Personalization

Press Releases

Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald

Tevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage Accounts

CD8 Technology Signs Letter of Intent for Tevogen Bio's In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment

Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest

Small Cap

Opinion

AI Healthcare Boom Gains Speed as Regulators and Innovators Align

Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation

Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting

Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow

Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships

Tevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars Initiatives

Comments

Tevogen Bio Holdings

Noticias

Últimas noticias sobre Tevogen Bio Holdings (NASDAQ:TVGN) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL